Mylan Acquires King For $4B In Move Toward Branded Drugs
The transaction was approved by the boards of both companies and is expected to close by the end of 2004, subject to regulatory and shareholder approvals. The board composition of Mylan will remain unchanged, Mylan said.
The deal was fueled by Mylan’s increasing focus...
To view the full article, register now.